Cyclerion Therapeutics Inc. [CYCN] has traded in a range of $1.69 to $14.77 in the last 1 year. As of this writing, the stock is at $3.69, down -48.13%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, CYCN shares are 13.56% up with the monthly amount drift of -2.47% and seems bad in a long time frame.
On 14, October 2020, Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease. According to news published on Yahoo Finance, Study results do not support further internal development.
In the past 52 weeks of trading, this stock has oscillated between a low of $1.69 and a peak of $14.77. Right now, according to Wall Street analyst the average 12-month amount target is $5.00. At the most recent market close, shares of Cyclerion Therapeutics Inc. [NASDAQ:CYCN] were valued at $3.69.
Cyclerion Therapeutics Inc. [NASDAQ:CYCN] most recently reported quarterly sales of 749.0 million, which represented growth of -56.30%. This publicly-traded organization’s revenue is $47,947 per employee, while its income is -$1,308,596 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -126.89, -281.86, -149.00 and -155.92 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 43.06 and the whole liability to whole assets at 39.64. It shows enduring liability to the whole principal at 41.07 and enduring liability to assets at 0.38 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 6.77 points at 1st support level, the second support level is making up to 6.42. But as of 1st resistance point, this stock is sitting at 7.33 and at 7.54 for 2nd resistance point.
Cyclerion Therapeutics Inc. [CYCN] reported its earnings at -$0.7 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.86/share signifying the difference of 0.16 and 18.60% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.73 calling estimates for -$0.87/share with the difference of 0.14 depicting the surprise of 16.10%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Cyclerion Therapeutics Inc. [NASDAQ:CYCN] is 3.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.35. Now if looking for a valuation of this stock’s amount to sales ratio it’s 16.52 and it’s amount to book ratio is 0.77.
The most recent insider trade was by Huyett William, Chief Financial Officer, and it was the sale of 3559.0 shares on Feb 21. Currie Mark G, the President, completed a sale of 25000.0 shares on Dec 30. On Dec 27, Currie Mark G, President, completed a sale of 25000.0 shares.